U.S. pharma huge copyright scrapped two experimental weight loss products previous 12 months—a once-day-to-day capsule, lotiglipron, as a consequence of elevated liver enzymes plus a twice-day-to-day tablet, danuglipron, as a result of potent side effects—but CEO Albert Bourla has claimed the company is decided to “Engage in and earn” durin